The Future of the Dual Axis Solar Tracker Market: Growth Trends, Market Size, and Opportunities to Watch
2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!
What Drivers Are Shaping the Growth and Development of theDuchenne Muscular Dystrophy (DMD) Therapeutics Market?
The anticipated expansion of the Duchenne muscular dystrophy (DMD) therapeutics market is thought to be driven by the increasing number of clinical trials. These are studies performed on humans to assess the safety, efficacy and potential advantages of new medical interventions or drugs. The growth in clinical trials specifically targeted on DMD treatment indicates ongoing research, innovation and wide-ranging therapeutic possibilities, all of which are poised to improve patient outcomes, lure investments and speed up the development and availability of effective treatments for Duchenne Muscular Dystrophy (DMD). Illustratively, Clinicaltrials.Gov, under The National Institutes Of Health (NIH), a US-based government agency tasked with conducting and supporting medical research, reported in August 2023 an increase in registered clinical trials to 464,218 from 399,496 in 2021 across all U.S. states and 221 countries. It also documented that 31% of these studies, equating to 142,700, are registered in the U.S. while 53% of them, translating to 248,310 studies, are in non-U.S. locations. Consequently, the growth of the Duchenne muscular dystrophy (DMD) therapeutics market is predicted to be driven by a surge in clinical trials. The Duchenne muscular dystrophy (DMD) market’s growth is speculated to be spurred by an upsurge in genetic disorders. Genetic disorders are medical conditions that result from abnormalities in a person’s DNA or genetic composition. An increase in genetic disorders implies a bigger population is potentially susceptible to DMD because of genetic mutations or familial genetic backgrounds. This results in an increased need for DMD-related diagnostics, treatments and therapeutic options. For example, according to the World Health Organization (WHO), a Switzerland-based intergovernmental organisation, birth abnormalities cause the deaths of 240,000 infants within the first month of life every year. Additionally, 170,000 children aged between one month and five years die as a result of birth abnormalities, including heart defects, neural tube defects and Down syndrome. Therefore, the rising incidence of genetic disorders is expected to propel the growth of the Duchenne muscular dystrophy (DMD) market.
Get Your Free Sample Report Now – Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12916&type=smp
#What is the Anticipated CAGR of theDuchenne Muscular Dystrophy (DMD) Therapeutics Market, and What Factors Will Drive It?
The market size for therapeutics related to Duchenne Muscular Dystrophy (DMD) has experienced considerable expansion in recent times. It is projected to increase from a valuation of $11.95 billion in the year 2024 to a whopping $16.45 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 37.6%. This notable growth during the historical period can be linked to escalating incidences of Duchenne Muscular Dystrophy, amplified awareness of DMD treatment options, enhanced investment in healthcare, and government-led initiatives.
In the forthcoming years, a substantial expansion is anticipated in the duchenne muscular dystrophy (DMD) therapeutics market. The market is projected to amplify to $47.34 billion in 2029, with a compound annual growth rate (CAGR) of 30.3%. The accelerated growth during the forecast period can be credited to increased funding for DMD treatments, embrace of combination therapies, emergence of biomarker, and a rising quantity of duchenne muscular dystrophy screening programs. The prediction period will showcase prominent trends such as innovative duchenne muscular dystrophy treatments, the advent of targeted therapies, the debut of new drugs and therapies, inventive disease-adjusting therapies, and dynamic pharmaceutical developments.
You can Directly Purchase the Report Here:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12916
Which Cutting-Edge Market Trends Are Expected to Drive theDuchenne Muscular Dystrophy (DMD) Therapeutics Market’s Growth?
Prominent companies functioning in the duchenne muscular dystrophy (DMD) therapeutics market are adopting innovative technolgies to boost the effectiveness and availability of DMD treatments and maintain their market dominance. One such example is Bit Bio Ltd., a synthetic biology firm based in the UK, introduced disease model goods in July 2023, to further DMD therapies. Known as the ioSkeletal Myocytes DMD Exon 44 Deletion and ioSkeletal Myocytes DMD Exon 52 Deletion, these are human skeletal myocytes exhibiting genetically modified deletions in the gene responsible for producing the dystrophin protein. Models from Bit. Bio, derived from induced pluripotent stem cells (iPSCs), offer a uniformly reliable and scalable resource for human cell research, tackling the issues related to variability and procuring primary cells. The models promote the progress of DMD treatments and provide insights into disease mechanisms and potential therapies. This could expedite the efforts of researchers who are looking for efficient DMD treatments.
What Are the Leading Market Players Impacting theDuchenne Muscular Dystrophy (DMD) Therapeutics Market’s Growth Trend?
Major companies operating in the duchenne muscular dystrophy (dmd) therapeutics market are CVS Health Corporation, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Co., Otsuka Holdings Co. Ltd., Daiichi Sankyo Co. Ltd., BioMarin Pharmaceutical Inc., Nippon Shinyaku Co. Ltd., CRISPR Therapeutics AG, Sarepta Therapeutics Inc., PTC Therapeutics Inc., Halozyme Therapeutics Inc., FibroGen Inc., Exonics Therapeutics Inc., Italfarmaco S.p.A., Wave Life Sciences Ltd., MeiraGTx Holdings PLC, Editas Medicine Inc., NS Pharma Inc., Solid Biosciences Inc., Santhera Pharmaceuticals Holding, Avidity Biosciences LLC, ReveraGen BioPharma Inc., Capricor Therapeutics Inc., Dynacure S.A., Summit Therapeutics plc.
Order Your Report Now For A Swift Delivery:
How Are the Key Segments of the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Driving Opportunities and Innovations?
The duchenne muscular dystrophy (DMD) therapeutics market covered in this report is segmented –
1) By Type: Small Molecules, Biologics
2) By Distribution Channel: Offline, Online
3) By Application: Hospitals, Clinics, Home Care
Subsegments:
1) By Small Molecules: Exon Skipping Therapies, Antisense Oligonucleotides, Read-Through Compounds
2) By Biologics: Gene Therapies, Cell Therapies, Protein Replacement Therapies
Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!
https://www.thebusinessresearchcompany.com/customise?id=12916&type=smp
What Regions Are At the Forefront of #What Drivers Are Shaping the Growth and Development of theDuchenne Muscular Dystrophy (DMD) Therapeutics Market?# Market Expansion?
North America was the largest region in the DMD therapeutics market in 2024. The regions covered in duchenne muscular dystrophy (DMD) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Browse Through More Reports Similar to the Global Duchenne Muscular Dystrophy (DMD) Therapeutics Market 2025, By The Business Research Company:
Interventional Neurology Devices And Equipment Global Market Report 2024
Central Nervous System Biomarkers Global Market Report 2024
Generic Central Nervous System Drugs Global Market Report 2024
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
